Abraxis Bioscience, LLC

The University of Texas System

Vivorx Pharmaceuticals, Inc.

Vivorx, Inc.

American Bioscience, Inc.

Fresenius Kabi Usa, LLC

Nantbioscience, Inc.

Mercator Medsystems, Inc.

Aadigen, LLC

Nant Holdingsip, LLC

Nantbio, Inc.

Novocell, Inc.

App Pharmaceuticals LLC

Clover Consolidated, Ltd.

Amcyte, Inc.

Neil P Desai

Patrick Soon-Shiong

Paul A Sandford

Vuong Trieu

Jeffrey Alan Hubbell

Amarpreet S Sawhney

Chandrashekhar Prabhakar Pathak

Chunlin Tao

Andrew Yang

Mark W Grinstaff

Kenneth S Suslick

Roswitha E Heintz

Jennifer L Hill

Syed F Hossainy

Viktor Peykov

Qinwei Wang

Michael Wong

Syed F A Hossainy

Daniel W Pierce

Jennifer L Hill-West

Willard Foss

Sherry Ci

Tapas De

Shlomo Magdassi

Xiaowen Sun

Zhiwen Yao

Markus Renschler

Roswitha A Heintz

Kirk Patrick Seward

Gilles Divita

David G Ho

Osmond D'Cruz

Soebianto Sojomihardjo

Laxman Nallan

Tulay Polat

Noma R Merideth

Cheng Zhi Yu

Zachary Yim

Leslie Louie

Xiping Liu

Daniel Knauer

Hongna Han

Shihe Hou

Sherry Xiaopei Ci

Qiang Yao

Chengzhi Yu

Tianli Zheng

Jeffrey A Hubbell

Stephen P Massia

P Soon-Shiong

Soebianto A Sojomihardjo

Andrew Sojomihardjo S

Francesco Curcio

Shubhi Nagrani

Cheng-Zhi Yu

Raj Selvaraj

Sherry Xiaopei Cl

Nilesh Ron

Lukasz Koroniak

David C Sahadevan

Soon-Shiong Patrick

Patrick M D Soon-Shiong

Chandrashekhar P Pathak

Kirk Seward

Bridget Beals Grim

Patrick Md Soon-Shiong

Patrick M Soon-Shiong

The present application is directed to cargo delivery complexes for intracellular delivery of a cargo molecule comprising: a first peptide comprising a cell-penetrating peptide (CPP), a second peptide comprising a cell-penetrating peptide, and a cargo molecule. The second peptide comprises a polyethylene glycol (PEG) moiety linked to the second CPP, and the first peptide does not have a PEG moiety. The present application is also directed to a cargo delivery complex comprising a CPP and a cargo molecule wherein the CPP is a retro-inverso peptide. The present application is also directed to a cargo delivery complex comprising a CPP and a cargo molecule wherein the peptide further comprises a targeting sequence selected from the group consisting of GYVSK, GYVS, YIGS and YIGSR. Methods of making and using the cargo delivery complexes are also disclosed.

Peptides and nanoparticles for intracellular delivery of molecules

The present application provides methods of treating a CNS disorder (such as glioblastoma and epilepsy) in an individual, comprising systemically (e.g., intravenously or subcutaneously) administering to the individual an effective amount of a composition comprising nanoparticles comprising an mTOR inhibitor (such as a limus drug, such as sirolimus or a derivative thereof) and an albumin, optionally further comprising administering a second agent (such as an anti-VEGF antibody, a proteasome inhibitor, or an alkylating agent).

Methods of treating central nervous system disorders via administration of nanoparticles of an mTOR inhibitor and an albumin

The present invention provides methods and compositions for treating epithelioid cell tumors (such as a PEComa) by administering a composition comprising nanoparticles comprising an mTOR inhibitor and an albumin.

Methods of treating epithelioid cell tumors

The present invention provides methods of assessing suitability of a pharmaceutical composition for medical use. The pharmaceutical composition comprises nanoparticles comprising rapamycin coated with albumin and a non-nanoparticle portion comprising albumin and rapamycin.

Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug

The present invention pertains to peptides and peptide-containing complexes/nanoparticles that are useful for stabilizing and delivering cargo molecules such as nucleic acids.

The present invention provides compositions (such as pharmaceutical compositions), and commercial batches of such compositions, comprising nanoparticles comprising albumin and rapamycin. The compositions (such as pharmaceutical compositions) have specific physicochemical characteristics and are particularly suitable for use in treating diseases such as cancer. Also provided are methods of making and methods of using the compositions (such as pharmaceutical compositions).

Pharmaceutical compositions of albumin and rapamycin

Methods of treating epithelioid cell tumors comprising administering a composition comprising nanoparticles comprising an mTOR inhibitor and an albumin

The present invention provides methods of assessing suitability of a pharmaceutical composition for medical use. The pharmaceutical composition comprises nanoparticles comprising paclitaxel coated with albumin and a non-nanoparticle portion comprising albumin and paclitaxel.

Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel

A container storing a liquid anesthetic solution is disclosed. The container is sealed by a closure, and the liquid anesthetic solution includes an anesthetic being from 0.1% to 10% by weight of the liquid anesthetic solution, water, and a solvent. The container includes a material that is inert to the anesthetic, and the closure includes siliconized rubber, a fluoropolymer, or metal that is inert to the anesthetic. The concentration of the anesthetic in the liquid anesthetic solution stored in the container following a predetermined time period is at least 93% of a concentration of the anesthetic in the liquid anesthetic solution before the liquid anesthetic solution is stored in the container.

Propofol formulations with non-reactive container closures

The present invention provides methods and compositions for treating non-small-cell lung cancer (NSCLC) by administering a) a composition comprising nanoparticles that comprise paclitaxel and an albumin and b) a platinum-based agent (e.g., carboplatin), wherein the individual has diabetes, has four or more metastatic sites, and/or is at least about 70 years old.

Methods of treating lung cancer

The present invention relates to methods and kits for the treatment of breast cancer based on hormone receptor status of progesterone receptor and estrogen receptor comprising the administration of a taxane alone, in combination with at least one other and other therapeutic agents, as well as other treatment modalities useful in the treatment of breast cancer. In particular, the invention relates to the use of nanoparticles comprising paclitaxel and albumin (such as Abraxane&#xae;) either alone or in combination with other chemotherapeutic agents or radiation, which may be used for the treatment of breast cancer which does not express estrogen receptor and/or progesterone receptor.

Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane

Growing community of inventors

Los Angeles, CA, United States of America

Neil P Desai